Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Bivalent COVID-19 vaccines that contain BA.1 or BA.4/BA.5 have been introduced worldwide in response to pandemic waves of Omicron subvariants. This prospective cohort study was aimed to compare neutralizing antibodies (Nabs) against Omicron subvariants (BA.1, BA.5, BQ.1.1, BN.1, and XBB.1) before and 3-4 weeks after bivalent booster by the types of SARS-CoV-2 variants in prior infections and bivalent vaccine formulations. A total of 21 participants were included. Prior BA.1/BA.2-infected, and BA.5-infected participants showed significantly higher geometric mean titers of Nab compared to SARS-CoV-2-non-infected participants after bivalent booster (BA.1, 8156 vs. 4861 vs. 1636; BA.5, 6515 vs. 4861 vs. 915; BQ.1.1, 697 vs. 628 vs. 115; BN.1, 1402 vs. 1289 vs. 490; XBB.1, 434 vs. 355 vs. 144). When compared by bivalent vaccine formulations, Nab titers against studied subvariants after bivalent booster did not differ between BA.1 and BA.4/BA.5 bivalent vaccine (BA.1, 4886 vs. 5285; BA.5, 3320 vs. 4118; BQ.1.1, 311 vs. 572; BN.1, 1028 vs. 1095; XBB.1, 262 vs. 362). Both BA.1 and BA.4/BA.5 bivalent vaccines are immunogenic and provide enhanced neutralizing activities against Omicron subvariants. However, even after the bivalent booster, neutralizing activities against the later Omicron strains (BQ.1.1, BN.1, and XBB.1) would be insufficient to provide protection.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10458764 | PMC |
| http://dx.doi.org/10.3390/vaccines11081320 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Immunogenicity and safety of 'Comvigen', a bivalent SARS-CoV-2 vaccine, in comparison to Comirnaty bivalent vaccine in Thailand: a phase 2, non-inferiority randomised trial.
Lancet Reg Health Southeast Asia
September 2025
Center of Excellence in Vaccine Research and Development (Chula Vaccine Research Center-Chula VRC), Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
Background: Strengthening mRNA vaccine development in LMICs is essential for enhancing global pandemic preparedness. This study evaluated the safety and immunogenicity of Comvigen, a bivalent SARS-CoV-2 vaccine, in comparison to the Comirnaty bivalent vaccine (Comirnaty).
Methods: This phase II, randomised, open-label, non-inferiority trial was conducted in Thailand across four centres.
Bivalent mRNA booster encoding virus-like particles elicits potent polyclass RBD antibodies in pre-vaccinated mice.
bioRxiv
August 2025
Gladstone Institutes, San Francisco, CA 94158, USA.
mRNA vaccines emerged as a leading vaccine technology during the COVID-19 pandemic. However, their sustained protective efficacies were limited by relatively short-lived antibody responses and the emergence of SARS-CoV-2 variants, necessitating frequent and variant-updated boosters. We recently developed the ESCRT- and ALIX-binding region (EABR) mRNA vaccine platform, which encodes engineered immunogens that induce budding of enveloped virus-like particles (eVLPs) from the plasma membrane, thereby resulting in presentation of immunogens on cell surfaces and eVLPs.
View Article and Find Full Text PDFBivalent RSV Prefusion F Protein-Based Vaccine for Preventing Cardiovascular Hospitalizations in Older Adults: A Prespecified Analysis of the DAN-RSV Trial.
JAMA
August 2025
Department of Cardiology, Copenhagen University Hospital-Herlev and Gentofte, Copenhagen, Denmark.
Importance: Respiratory syncytial virus (RSV) infection is linked to elevated cardiovascular risk, particularly in individuals with preexisting cardiovascular disease (CVD). A bivalent RSV prefusion F protein (RSVpreF) vaccine was recently approved for preventing RSV-related lower respiratory tract illness, but its effectiveness against cardiovascular outcomes has not been evaluated in a randomized trial.
Objective: To investigate the vaccine effectiveness of RSVpreF compared with no vaccine against cardiovascular outcomes among adults aged 60 years or older.
Safety and efficacy of an intramuscular bivalent vaccine against influenza and Streptococcus pneumoniae infections in mice.
Med Microbiol Immunol
August 2025
Grupo Integrado de Pesquisa em Biomarcadores, Instituto René Rachou - Fundação Oswaldo Cruz, Avenida Augusto de Lima nº 1715, Barro Preto, Belo Horizonte, Minas Gerais, Brasil.
Influenza virus and Streptococcus pneumoniae are major respiratory pathogens responsible for significant global mortality. While influenza causes seasonal flu, pneumococcus is associated with pneumonia, meningitis, sepsis, and otitis, often worsening influenza cases through secondary infections. Aiming to develop a bivalent vaccine against these two pathogens, we used reverse genetics to construct a recombinant influenza virus that carries the gene of the pneumococcal PspA protein (Flu-PspA).
View Article and Find Full Text PDFCOVID-19 vaccine effectiveness and duration of protection among children and adolescents: A retrospective cohort study in 11 large cities in Japan.
Vaccine
August 2025
Center for Infectious Disease Epidemiology, the National Institute of Infectious Diseases, Japan Institute for Health Security, Tokyo, Japan.
Introduction: COVID-19 vaccination for children has been debatable. Compiling scientific evidence on vaccine safety and effectiveness was indispensable for the effective vaccine strategy. This study aimed to estimate the effectiveness and protection duration of the COVID-19 vaccine among children and adolescents in Japan.
View Article and Find Full Text PDF